Searchicon: search

Helping you stay one step ahead of clostridial risks

Discover the BOVILIS® clostridial vaccine portfolio featuring options for 8, 9 and 10-way coverage against clostridia.

The natural habitats of clostridia (anaerobic, gram-positive organisms that are found either as living cells or dormant spores) are soils and the intestinal tracts of animals.1

Pathogenic strains or their toxins may be acquired by susceptible animals, either by wound contamination or ingestion.1 Clostridial diseases strike quickly and often fatally, making them a constant threat to successful cattle production in many parts of the world.1

Vaccination decreases the need for the use of antibiotics, which, in turn, reduces the risk of antimicrobial resistance.

The Merck Animal Health BOVILIS® line of clostridial vaccines include extensive and flexible coverage against important clostridial pathogens. The portfolio contains the only 8, 9 and 10-way clostridial vaccines available in Canada that include coverage against tetanus.*

*Always read and follow label instructions to ensure the selected product is suitable for the animal to be vaccinated. Vaccination may not protect every animal that gets vaccinated.

Bovilis® Covexin® 10

The only vaccine that provides 10-way coverage against clostridial diseases, including tetanus and Clostridium perfringens Type A

  • Dose volume: 2 mL
  • Administration: Subcutaneous
Product label

Bovilis® Covexin® Plus

Provides 9-way coverage against clostridial diseases, including tetanus.

  • Dose volume: 2 mL
  • Administration: Subcutaneous
Product label

Bovilis® Tasvax® 8

Provides 8-way coverage against clostridial diseases, including tetanus.

  • Dose volume: 4 mL
  • Administration: Subcutaneous
Product label

Bovilis® Vision® 8 with SPUR®

Low-volume, low-reactive 8-way clostridial vaccine with unique advanced antigen delivery.

  • Dose volume: 2 mL
  • Administration: Subcutaneous
Product label

Bovilis® Vision® 8 Somnus with SPUR®

Dual clostridial disease and haemophilosis coverage in a low-volume vaccine with unique advanced antigen delivery.

  • Dose volume: 2 mL
  • Administration: Subcutaneous
Product label

References

  1. Stämpfi HR. Overview of clostridial diseases. Merck Veterinary Manual. Available at https://www.merckvetmanual.com/generalized-conditions/clostridial-diseases/overview-of-clostridial-diseases (consulted May 30, 2025).

BOVILIS®, SPUR® and VISION® are registered trademarks of Intervet International B.V. COVEXIN® and TASVAX® are registered trademarks of Intervet Inc. All trademarks used under license.